文献速递临床试验与 GCP真实世界研究与卫生经济

复苏性血管内球囊阻断主动脉(REBOA)用于创伤患者不可控躯干出血的有效性与成本效果:英国REBOA试验随机临床试验研究方案

The effectiveness and cost-effectiveness of resuscitative endovascular balloon occlusion of the aorta (REBOA) for trauma patients with uncontrolled torso haemorrhage: study protocol for a randomised clinical trial (the UK-REBOA trial).
PubMed 文献 · Trials · 2022-05-12

本研究为在英格兰16家主要创伤中心开展的实用性、贝叶斯、组序贯随机对照试验,计划随机分配120例疑似致命性出血的创伤患者,比较标准主要创伤中心治疗联合REBOA与单纯标准治疗。主要临床结局为90天死亡率,主要经济结局为终生增量成本每获得一个QALY。该研究首次将患者随机分配至REBOA或标准治疗,旨在提供REBOA临床与成本效果的高级别证据。

要点

  • 英国REBOA试验在16家主要创伤中心随机分配120例疑似致命性出血的创伤患者。
  • 主要临床结局为90天死亡率,主要经济结局为终生增量成本每QALY。
  • 该研究首次将患者随机分配至REBOA或标准治疗,旨在提供高级别证据。

核心结论

  • 该研究将提供REBOA用于创伤致命性出血患者临床与成本效果的高级别证据,并提供REBOA纳入主流临床实践可行性的重要数据。

研究设计与样本

  • 实用性、贝叶斯、组序贯随机对照试验,在英格兰16家主要创伤中心开展。
  • 计划随机分配120例疑似致命性出血的创伤患者至标准主要创伤中心治疗联合REBOA组或单纯标准主要创伤中心治疗组。

主要发现

  • 主要临床结局为90天死亡率。
  • 次要临床结局包括3小时、6小时和24小时死亡率;院内死亡率;6个月死亡率;住院和重症监护室停留时间;24小时血制品使用;需要出血控制操作(手术或血管内栓塞);以及开始出血控制操作(REBOA、手术或血管内栓塞)的时间。
  • 主要经济结局为从健康与个人社会服务角度计算的终生增量成本每获得一个QALY。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Haemorrhage is the most common cause of preventable death after injury. REBOA is a novel technique whereby a percutaneously inserted balloon is deployed in the aorta, providing a relatively quick means of temporarily controlling haemorrhage and augmenting cerebral and coronary perfusion, until definitive control of haemorrhage can be attained. The aim of the UK-REBOA trial is to establish the clinical and cost-effectiveness of a policy of standard major trauma centre treatment plus REBOA, as compared with standard major trauma centre treatment alone, for the management of uncontrolled torso haemorrhage caused by injury. METHODS: Pragmatic, Bayesian, group-sequential, randomised controlled trial, performed in 16 major trauma centres in England. We aim to randomise 120 injured patients with suspected exsanguinating haemorrhage to either standard major trauma centre care plus REBOA or standard major trauma centre care alone. The primary clinical outcome is 90-day mortality. Secondary clinical outcomes include 3-h, 6-h, and 24-h mortality; in-hospital mortality; 6-month mortality; length of stay (in hospital and intensive care unit); 24-h blood product use; need for haemorrhage control procedure (operation or angioembolisation); and time to commencement of haemorrhage control procedure (REBOA, operation, or angioembolisation). The primary economic outcome is lifetime incremental cost per QALY gained, from a health and personal social services perspective. DISCUSSION: This study, which is the first to randomly allocate patients to treatment with REBOA or standard care, will contribute high-level evidence on the clinical and cost-effectiveness of REBOA in the management of trauma patients with exsanguinating haemorrhage and will provide important data on the feasibility of implementation of REBOA into mainstream clinical practice. TRIAL REGISTRATION: ISRCTN16184981.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jansen JO, Cochran C, Boyers D, et al. The effectiveness and cost-effectiveness of resuscitative endovascular balloon occlusion of the aorta (REBOA) for trauma patients with uncontrolled torso haemorrhage: study protocol for a randomised clinical trial (the UK-REBOA trial). Trials. 2022. PMID: 35550642. doi:10.1186/s13063-022-06346-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。